What is the Lundbeck v. Vyepti patent dispute about?
I couldn’t locate enough specific information in the provided materials to accurately describe a “Lundbeck v. Vyepti” patent case (for example, which patent numbers, the asserted claims, the filing dates, or the relief sought). “Vyepti” is eptinezumab (an anti-CGRP monoclonal antibody), and “Lundbeck” has a history of migraine-related IP activity, but the exact dispute details matter to answer correctly.
If you can share any of the following, I can give a precise, sourced explanation:
- the case caption or court (e.g., “Lundbeck v. [company]” or “Lundbeck et al. v. …”)
- the forum (federal court vs. ITC, PTAB, etc.)
- patent number(s) or publication numbers
- the drug name of the challenger/ANDA/BLA applicant (if it’s tied to an exclusivity/patent listing)
Which Vyepti patents are usually relevant to challenges?
For Vyepti-related litigation, the patents most often implicated in U.S. disputes tend to include:
- composition-of-matter patents (the antibody or specific antibody sequences)
- formulation/drug-product patents (how the drug is made or delivered)
- method-of-use patents (treatment regimens, patient populations, dosing)
To map the “Lundbeck v. Vyepti” dispute to the likely patent type(s), I would need the specific patent numbers asserted in that case.
When does Vyepti patent/exclusivity typically expire?
Patent and exclusivity timelines depend on the specific patent (each can expire on different dates) and whether the challenge is tied to:
- U.S. patent term expiration (including any adjustments)
- FDA marketing exclusivity (like biologics exclusivity)
- regulatory exclusivity triggers (which can differ from patent expiry)
With the asserted patent numbers, I can point to the exact expiration(s) and explain how they affect market entry.
Can biosimilars enter before the patents expire?
In principle, even if a biosimilar or interchangeable product is approved, patent law can still block commercial launch until the relevant patents expire (or are held invalid/not infringed). The key question is whether the challenge is under the Hatch-Waxman/BPCIA-type framework and which patents are the “blocking” ones for the product at issue.
Where can I verify the exact “Lundbeck v. Vyepti” patents and litigation?
DrugPatentWatch.com is a good starting point for identifying the relevant patents and (often) mapping litigation to listed IP, but I need the exact disputed patent or the opposing company to pull the correct track.
If you tell me the opponent’s name or the patent number, I can align the dispute to the correct Vyepti IP listing and summarize it accurately.
Source to use (once we have the right identifier):
- DrugPatentWatch.com (Vyepti/eptinezumab patent and exclusivity tracking): https://www.drugpatentwatch.com/
What I need from you to answer precisely
Reply with one of these and I’ll produce a tight, accurate summary of the Lundbeck v. Vyepti patent dispute:
1) the full case name/caption, or
2) the court and year, or
3) the patent number(s), or
4) the other party’s name (the company being sued or challenging).
Sources
- https://www.drugpatentwatch.com/